​

ESSA Pharma (EPIX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

EPIX Stock Forecast

ESSA Pharma (EPIX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $9.50, with a high of $17.00 and a low of $2.00. This represents a 458.82% increase from the last price of $1.70.

- $4 $8 $12 $16 $20 High: $17 Avg: $9.5 Low: $2 Last Closed Price: $1.7

EPIX Stock Rating

ESSA Pharma stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (50.00%), 2 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 2 2 Strong Sell Sell Hold Buy Strong Buy

EPIX Price Target Upside V Benchmarks

TypeNameUpside
StockESSA Pharma458.82%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$11.33
Last Closing Price$1.70$1.70$1.70
Upside/Downside--566.47%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--2--2
May, 25--3--3
Apr, 25--3--3
Mar, 25--4--4
Feb, 25--4--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 04, 2024Joseph CatanzaroPiper Sandler$2.00$1.6322.70%17.65%
Sep 16, 2024Leland GershellOppenheimer$17.00$6.85148.18%900.00%
Sep 16, 2024Tyler Van BurenPiper Sandler$15.00$6.85118.98%782.35%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024Piper SandlerOverweightNeutraldowngrade
Nov 04, 2024OppenheimerOutperformPerformdowngrade
Sep 16, 2024OppenheimerOutperformOutperformhold
Sep 16, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28
Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28
Reported$-0.60-----
Avg Forecast$-0.69$-0.68$-0.56$-0.32$-0.33$-0.32
High Forecast$-0.68$-0.64$-0.43$0.32$0.73$-0.32
Low Forecast$-0.71$-0.73$-0.81$-0.98$-2.60$-0.32
Surprise %-13.04%-----

Revenue Forecast

$20M $26M $32M $38M $44M $50M Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28
Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28
Reported------
Avg Forecast---$22.27M$42.26M$45.04M
High Forecast---$22.27M$42.26M$45.04M
Low Forecast---$22.27M$42.26M$45.04M
Surprise %------

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28
Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28
Reported$-26.58M-----
Avg Forecast$-30.82M$-28.54M$-23.00M$-17.45M$24.81M$-14.17M
High Forecast$-30.16M$-28.30M$-18.83M$14.17M$32.24M$-14.17M
Low Forecast$-31.47M$-32.16M$-35.84M$-43.39M$-115.15M$-14.17M
Surprise %-13.74%-----

EPIX Forecast FAQ

Is ESSA Pharma stock a buy?

ESSA Pharma stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ESSA Pharma is a favorable investment for most analysts.

What is ESSA Pharma's price target?

ESSA Pharma's price target, set by 4 Wall Street analysts, averages $9.5 over the next 12 months. The price target range spans from $2 at the low end to $17 at the high end, suggesting a potential 458.82% change from the previous closing price of $1.7.

How does ESSA Pharma stock forecast compare to its benchmarks?

ESSA Pharma's stock forecast shows a 458.82% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for ESSA Pharma over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is ESSA Pharma’s EPS forecast?

ESSA Pharma's average annual EPS forecast for its fiscal year ending in September 2024 is $-0.68, marking a 13.33% increase from the reported $-0.6 in 2023. Estimates for the following years are $-0.56 in 2025, $-0.32 in 2026, $-0.33 in 2027, and $-0.32 in 2028.

What is ESSA Pharma’s revenue forecast?

ESSA Pharma's average annual revenue forecast for its fiscal year ending in September 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $22.27M for 2026, $42.26M for 2027, and $45.04M for 2028.

What is ESSA Pharma’s net income forecast?

ESSA Pharma's net income forecast for the fiscal year ending in September 2024 stands at $-28.543M, representing an 7.38% increase from the reported $-26.582M in 2023. Projections indicate $-22.996M in 2025, $-17.445M in 2026, $24.81M in 2027, and $-14.169M in 2028.